All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-01-18T17:07:42.000Z

BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?

By Paola Frisone, Joshua Reid
Featured
Nitin Jain
Jan 18, 2021
Share:

Bookmark this article

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Nitin Jain, MD Anderson Cancer Center, Houston, US. We asked, Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?

BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?

Jain provides an update on a trial evaluating UCART22 in adult patients with relapsed/refractory B-cell ALL. Jain starts by discussing the advantages of using allogeneic T-cell products. He then discusses the safety and efficacy results of the trial and finishes by outlining future adjustments of protocols to promote the persistence of UCART22.

More about...
ASH 2020B-cell ALLBALLI-01CAR therapyUCART22

Related articles

Add bookmark

Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL

Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two anti-CD19 chimeric antigen receptor (CAR) T-cell...

Feb 25, 2021
Add bookmark

Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL

Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...

Feb 25, 2021
Add bookmark

Genetic markers in the prognosis of patients with ALL

Despite much research, the mutational landscape of patients with acute lymphoblastic leukemia (ALL) remains relatively poorly characterized, especially for rarer subtypes.

Feb 22, 2021
Add bookmark

Genetic markers in the prognosis of patients with ALL

Despite much research, the mutational landscape of patients with acute lymphoblastic leukemia (ALL) remains relatively poorly characterized,...

Feb 22, 2021

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox